Back to Search
Start Over
Satraplatin Demonstrates High Cytotoxic Activity Against Genetically Defined Lymphoid Malignancies
- Source :
- Anticancer Research. 42:1821-1832
- Publication Year :
- 2022
- Publisher :
- Anticancer Research USA Inc., 2022.
-
Abstract
- Satraplatin is an oral platinum analog with proven clinical efficacy and a more favorable toxicity profile, although with increased hematotoxicity, when compared to cisplatin. Hence, we carried out a systematic biomarker analysis to identify hematological malignancies with high susceptibility to satraplatin.Half-maximal inhibitory concentrations (ICSatraplatin was significantly more active against hematological malignancies compared to solid organ cancer. In addition, satraplatin showed a significantly more potent antiproliferative activity compared to cisplatin in most lymphoma cell lines achieving sub micromolar ICSatraplatin demonstrated a high cytotoxic activity in genetically well-defined hematological malignancies which is distinct from that of cisplatin. MTAP deficiency was identified as biomarker of enhanced satraplatin efficacy in hematological cancer-derived cell lines. These data in combination with the lipophilicity of satraplatin provide the rationale for targeting specific lymphatic entities such as primary central nervous system lymphoma and cutaneous T-cell lymphoma to improve clinical outcome.
Details
- ISSN :
- 17917530 and 02507005
- Volume :
- 42
- Database :
- OpenAIRE
- Journal :
- Anticancer Research
- Accession number :
- edsair.doi.dedup.....88c4b38ed4c96861f90fd2d18e1697f3
- Full Text :
- https://doi.org/10.21873/anticanres.15658